Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data

Am Heart J. 1999 May;137(5):S123-5. doi: 10.1016/s0002-8703(99)70445-x.
No abstract available

MeSH terms

  • Abciximab
  • Angioplasty, Balloon, Coronary / economics
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use
  • Cardiovascular Diseases / economics*
  • Cardiovascular Diseases / therapy
  • Clinical Trials as Topic
  • Cost of Illness*
  • Cost-Benefit Analysis
  • Economics, Pharmaceutical
  • Hospital Costs*
  • Humans
  • Immunoglobulin Fab Fragments / economics*
  • Immunoglobulin Fab Fragments / therapeutic use
  • Platelet Aggregation Inhibitors / economics*
  • Platelet Aggregation Inhibitors / therapeutic use
  • United States

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Abciximab